Increase in Antibody Titers Following Sars-Cov-2 Vaccination Remains Limited for More Than 3 Years after Final Dose of Anti-CD20 Antibody

COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global pandemic. Patients with hematological disorders are known to be at high risk of morbidity and mortality from COVID-19, and vaccines against SARS-CoV-2 have been rapidly developed. Although mRNA vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Funakoshi, Yohei, Yakushijin, Kimikazu, Ohji, Goh, Sakai, Hironori, Hojo, Wataru, Watanabe, Marika, Saeki, Miki, Hirakawa, Yuri, Sakai, Rina, Matsumoto, Sakuya, Mizutani, Yu, Kitao, Akihito, Miyata, Yoshiharu, Saito, Yasuyuki, Kawamoto, Shinichiro, Katsuya, Yamamoto, Ito, Mitsuhiro, Nishimura, Meiko, Imamura, Yoshinori, Kiyota, Naomi, Matsuoka, Hiroshi, Mori, Yasuko, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
627.Aggressive Lymphomas: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701599/
http://dx.doi.org/10.1182/blood-2021-148981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701599/
http://dx.doi.org/10.1182/blood-2021-148981

Ejemplares similares